Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma

D. Mahalingam, C. M. Espitia, E. C. Medina, J. A. Esquivel, K. R. Kelly, D. Bearss, G. Choy, P. Taverna, J. S. Carew, F. J. Giles, S. T. Nawrocki

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Background: Upregulation of PIM kinase expression has been reported in many malignancies, suggesting that inhibition of PIM kinase activity may be an attractive therapeutic strategy. We hypothesised that inhibition of PIM kinase activity with SGI-1776, a novel small molecule inhibitor of PIM kinase activity, would reduce the viability of renal cell carcinoma (RCC) cells and enhance the activity of sunitinib. Methods: Immunoblotting, qRT-PCR, and gene expression arrays were carried out to identify genes modulated by SGI-1776 treatment. The anticancer activity of SGI-1776 and sunitinib was determined by viability and apoptosis assays and in tumour xenografts in vivo. Results: Treatment with SGI-1776 led to a decrease in phosphorylated and total c-Myc levels, which resulted in the modulation of c-Myc target genes. SGI-1776 in combination with sunitinib induced a further reduction in c-Myc levels, which was associated with enhanced anticancer activity. siRNA-mediated knockdown of c-Myc demonstrated that its expression has a key role in regulating the sensitivity to the combination of SGI-1776 and sunitinib. Importantly, the combination significantly reduced tumour burden in two RCC xenograft models compared with single-agent therapy and was very well tolerated. Conclusion: These data indicate that targeting PIM kinase signalling is a promising treatment strategy for RCC.

Original languageEnglish (US)
Pages (from-to)1563-1573
Number of pages11
JournalBritish Journal of Cancer
Volume105
Issue number10
DOIs
StatePublished - Nov 8 2011

Keywords

  • PIM
  • SGI-1776
  • c-Myc
  • renal cell carcinoma
  • sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Mahalingam, D., Espitia, C. M., Medina, E. C., Esquivel, J. A., Kelly, K. R., Bearss, D., Choy, G., Taverna, P., Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2011). Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. British Journal of Cancer, 105(10), 1563-1573. https://doi.org/10.1038/bjc.2011.426